申请人:Hoffmann-La Roche Inc.
公开号:US06291465B1
公开(公告)日:2001-09-18
The invention relates to compounds of the formula
wherein
R is hydrogen, lower alkyl, lower alkoxy halogen, amino, —N(R6)2 or trifluoromethyl;
R1 is hydrogen lower alkoxy or halogen,
R and R1 may be together —CH═CH—CH═CH—;
R2 is halogen, lower alkyl or trifluoromethyl;
R3 is hydrogen or lower alkyl;
R4 is hydrogen or a cyclic tertiary amine, optionally substituted by lower alkyl;
R5 is hydrogen, nitro, amino or —N(R6)2;
R6 is hydrogen or lower alkyl,
X is —C(O)N(R6)—, —(CH2)nO—, (CH2)nN(R6)—, —N(R6)C(O)— or —N(R6)(CH2)n—; and
n is 1 or 2;
and pharmaceutically acceptable acid addition salts thereof.
The compounds of formula I may be used for the treatment of diseases related to the NK-1 receptor.
本发明涉及下列化合物的公式:其中,R表示氢、低级烷基、低级烷氧基、卤素、氨基、—N(R6)2或三氟甲基;R1表示氢、低级烷氧基或卤素;R和R1可以是—CH═CH—CH═CH—;R2表示卤素、低级烷基或三氟甲基;R3表示氢或低级烷基;R4表示氢或环状三级胺,可选择性地被低级烷基取代;R5表示氢、硝基、氨基或—N(R6)2;R6表示氢或低级烷基;X表示—C(O)N(R6)—、—(CH2)nO—、(CH2)nN(R6)—、—N(R6)C(O)—或—N(R6)(CH2)n—;n为1或2;以及其药学上可接受的酸加盐。公式I的化合物可用于治疗与NK-1受体相关的疾病。